4.6 Article

MAJOR DEPRESSIVE DISORDER SUBTYPES TO PREDICT LONG-TERM COURSE

Journal

DEPRESSION AND ANXIETY
Volume 31, Issue 9, Pages 765-777

Publisher

WILEY
DOI: 10.1002/da.22233

Keywords

epidemiology; depression; anxiety; anxiety disorders; suicide; self-harm; panic attacks

Funding

  1. National Institute of Mental Health (NIMH) [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. U.S. Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly & Company Foundation
  8. Ortho-McNeil Pharmaceutical, Inc.
  9. GlaxoSmithKline
  10. Sanofi Aventis
  11. Bristol-Myers Squibb
  12. VICI from the Netherlands Research Foundation (NWO-ZonMW) [91812607]
  13. State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
  14. Ministry of Health
  15. National Center for Public Health Protection
  16. Shenzhen Bureau of Health
  17. Shenzhen Bureau of Science, Technology, and Information
  18. Ministry of Social Protection
  19. Japanese and European funds through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  20. Israel National Institute for Health Policy and Health Services Research
  21. National Insurance Institute of Israel
  22. Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]
  23. Lebanese Ministry of Public Health
  24. WHO (Lebanon)
  25. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  26. Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
  27. AstraZeneca
  28. Eli Lilly
  29. Hikma Pharm
  30. Pfizer
  31. Roche
  32. Sanofi-Aventis
  33. Servier
  34. Novartis
  35. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  36. National Council on Science and Technology [CONACyT-G30544-H]
  37. PanAmerican Health Organization (PAHO)
  38. New Zealand Ministry of Health
  39. Alcohol Advisory Council
  40. Health Research Council
  41. WHO (Geneva)
  42. WHO (Nigeria)
  43. Federal Ministry of Health, Abuja, Nigeria
  44. Health and Social Care Research and Development Division of the Public Health Agency
  45. Champalimaud Foundation
  46. Gulbenkian Foundation
  47. Foundation for Science and Technology (FCT)
  48. Ministry of Public Health
  49. U.S. National Institute of Mental Health [RO1-MH61905]
  50. National Institute of Drug Abuse (NIDA)
  51. Substance Abuse and Mental Health Services Administration (SAMHSA)
  52. Robert Wood Johnson Foundation (RWJF) [044708]
  53. John W. Alden Trust
  54. Janssen Pharmaceuticals
  55. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP
  56. Medical Research Council [MR/K023241/1] Funding Source: researchfish
  57. Public Health Agency [COM/4437/11, COM/4411/10] Funding Source: researchfish
  58. MRC [MR/K023241/1] Funding Source: UKRI

Ask authors/readers for more resources

BackgroundVariation in the course of major depressive disorder (MDD) is not strongly predicted by existing subtype distinctions. A new subtyping approach is considered here. MethodsTwo data mining techniques, ensemble recursive partitioning and Lasso generalized linear models (GLMs), followed by k-means cluster analysis are used to search for subtypes based on index episode symptoms predicting subsequent MDD course in the World Mental Health (WMH) surveys. The WMH surveys are community surveys in 16 countries. Lifetime DSM-IV MDD was reported by 8,261 respondents. Retrospectively reported outcomes included measures of persistence (number of years with an episode, number of years with an episode lasting most of the year) and severity (hospitalization for MDD, disability due to MDD). ResultsRecursive partitioning found significant clusters defined by the conjunctions of early onset, suicidality, and anxiety (irritability, panic, nervousness-worry-anxiety) during the index episode. GLMs found additional associations involving a number of individual symptoms. Predicted values of the four outcomes were strongly correlated. Cluster analysis of these predicted values found three clusters having consistently high, intermediate, or low predicted scores across all outcomes. The high-risk cluster (30.0% of respondents) accounted for 52.9-69.7% of high persistence and severity, and it was most strongly predicted by index episode severe dysphoria, suicidality, anxiety, and early onset. A total symptom count, in comparison, was not a significant predictor. ConclusionsDespite being based on retrospective reports, results suggest that useful MDD subtyping distinctions can be made using data mining methods. Further studies are needed to test and expand these results with prospective data. (C) 2014 Wiley Periodicals, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available